Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 5:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–7 of 7 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: BRAVO capsule Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Influence of Central Obesity on the Esophageal Epithelial Barrier

NCT02776982
View directory record Official record
Conditions
Gastroesophageal Reflux, GERD
Interventions
Confocal endomicroscopy, Mucosal impedance, Research biopsies, Bravo ambulatory pH monitor
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Sep 10, 2026, 5:58 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis

NCT01047319
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Laquinimod
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
Not listed
Enrollment
1,047 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
22
States / cities
Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Sep 10, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

NCT00605215
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Laquinimod, Placebo, Avonex®
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Sep 10, 2026, 5:58 AM EDT
Completed Not applicable Interventional Results available

Feasibility of Placing Bravo PH Capsule in Proximal Esophagus

NCT00378898
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
BRAVO capsule, Fluoroscopy, sham BRAVO capsule placement
Device · Procedure · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 10, 2026, 5:58 AM EDT
Enrolling by invitation No phase listed Observational

Assessment of Esophageal Epithelium Integrity With Use of a Novel Mucosal Impedance Device

NCT03103789
View directory record Official record
Conditions
Gastro Esophageal Reflux
Interventions
single catheter mucosal impedance testing, balloon assembly mucosal impedance testing
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
75 participants
Timeline
2014 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 10, 2026, 5:58 AM EDT
Not yet recruiting Not applicable Interventional

PROPER-GERD: A Prospective Crossover Study to Evaluate Probe Placement Optimization for Reflux Testing in Women and Lower-BMI Patients

NCT07716592
View directory record Official record
Conditions
GERD
Interventions
Bravo pH monitoring sessions
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 10, 2026, 5:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule

NCT00579410
View directory record Official record
Conditions
Esophagitis, Inflammation, Gastritis, Abdominal Pain, Heartburn
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 21, 2011 · Synced Sep 10, 2026, 5:58 AM EDT